The full TRIUMPH-1 safety dataset clarified the retatrutide dysesthesia signal: 20.9% of patients on 12 mg reported tingling, tenderness, or altered sensation, versus 8.8% at 9 mg and 0.7% on placebo. The signal is dose-dependent, generally mild to moderate, and Lilly says it is being monitored across all ongoing TRIUMPH trials. The data sit alongside the arrhythmia signal (7/403 retatrutide, 3 MACE versus 0 placebo) that STAT flagged on June 6 and now constitute the field's main retatrutide-specific safety conversation.
The TRIUMPH-1 dysesthesia signal (skin tingling, paresthesia-like sensations) that BMO Capital flagged Thursday merits a mechanistic look. The signal appeared in 12.5% of participants on retatrutide 12 mg in TRIUMPH-1, but was NOT reported in the Phase 2 retatrutide program. TRIUMPH-4 (December 2025 readout) recorded dysesthesia in approximately 20.9% of participants on the highest dose — most cases mild and resolving during ongoing treatment. The mechanistic explanation is tied to retatrutide's glucagon-receptor activation: glucagon signaling drives small-fiber sensory neuropathy patterns through downstream effects on c-AMP-mediated nociceptor sensitization. The pattern is dose-dependent (4 mg essentially no signal, 9 mg modest, 12 mg the peak). The clinical question is whether dysesthesia stays mild and reversible at commercial scale or whether a small fraction of patients develop persistent or more severe sensory disturbances. The signal is the differentiator from tirzepatide (no glucagon arm) and semaglutide (no glucagon, no GIP).
Day-after analyst reaction to Lilly's May 21 TRIUMPH-1 topline split between efficacy enthusiasm and tolerability caution. LLY shares rose roughly 1% in Thursday premarket trading. William Blair noted that retatrutide's 11.3% discontinuation rate on 12 mg plus the dysesthesia signal (skin tingling, 12.5% of 12 mg participants — a finding not reported in Phase 2 data) probably confines the drug to higher-BMI patient populations, with tirzepatide remaining the volume agent at the moderate-BMI tier. BMO Capital Markets specifically flagged the dysesthesia signal as worth monitoring in subsequent readouts and the TRIUMPH-4 follow-on detail. Manak Mahmood at Pharma Intelligence framed the data as 'very impressive' but noted ADA 2026 full data presentation in two weeks will be critical for the obesity-market positioning. The GI side-effect profile at 12 mg — nausea 42.4%, vomiting 25.3%, diarrhea 32.0% — is the tolerability gap that prescribers will weigh against the efficacy gain over tirzepatide.